Compare QUIK & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | CRBP |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.5M | 134.8M |
| IPO Year | 1997 | 2014 |
| Metric | QUIK | CRBP |
|---|---|---|
| Price | $8.57 | $9.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $11.00 | ★ $46.17 |
| AVG Volume (30 Days) | ★ 182.5K | 152.1K |
| Earning Date | 06-03-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,112,000.00 | $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.38 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $4.26 | $4.64 |
| 52 Week High | $9.59 | $20.56 |
| Indicator | QUIK | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 68.49 |
| Support Level | $5.96 | $9.58 |
| Resistance Level | $9.27 | $11.64 |
| Average True Range (ATR) | 0.60 | 0.56 |
| MACD | 0.08 | 0.18 |
| Stochastic Oscillator | 53.85 | 100.00 |
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.